The filing content cuts off before the financial statements are included, but there is sufficient substantive disclosure content (company identity, filing type, period, share count, exchange listing, and filing context) to clear the 150-word threshold. I will now produce the article based on what is available in the filing.

Shattuck Labs, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 5, 2026, disclosing its financial position and operations as a clinical-stage biopharmaceutical company.

Key Highlights

  • Share count: As of November 2, 2026, the registrant had 101,842,552 shares of common stock, $0.0001 par value per share, outstanding.
  • Exchange listing: Common stock is listed on The Nasdaq Global Select Market under the trading symbol STTK.
  • Reporting period: The quarterly report covers the three and nine months ended September 30, 2026, with comparative periods ended September 30, 2025.
  • Filer classification: The company identified itself as a non-accelerated filer and a smaller reporting company, and indicated it is not an emerging growth company.
  • Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.
  • Principal offices: The company is headquartered at 500 W. 5th Street, Suite 1200, Austin, TX 78701.

Shattuck Labs Reports Q3 2026 Filing Status and Share Count

Shattuck Labs, Inc. (NASDAQ:STTK) submitted its quarterly report on Form 10-Q for the period ended September 30, 2026, according to the filing. The company, incorporated in Delaware with IRS Employer Identification Number 81-2575858, holds Commission File Number 001-39593. As of November 2, 2026, the registrant reported 101,842,552 shares of common stock outstanding, each with a par value of $0.0001 per share.

According to the filing, the registrant confirmed it has filed all reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and has submitted all required Interactive Data Files electronically. The company classified itself as a non-accelerated filer and a smaller reporting company, and confirmed it is not an emerging growth company and has not elected an extended transition period for new accounting standards.

The 10-Q filing includes condensed balance sheets as of September 30, 2026 and December 31, 2025, condensed statements of operations and comprehensive loss for the three and nine months ended September 30, 2026 and 2025, condensed statements of changes in stockholders' equity, and condensed statements of cash flows for the nine months ended September 30, 2026 and 2025, the filing disclosed. The company noted that its forward-looking statements are subject to substantial risks and uncertainties, including those related to clinical trial timing, regulatory approvals, financing needs, and macroeconomic conditions, and cautioned that readers should not place undue reliance on such statements.

What Was Disclosed

Shattuck Labs filed its Q3 2026 Form 10-Q covering the period ended September 30, 2026, reporting 101,842,552 shares of common stock outstanding as of November 2, 2026, and confirming its listing on The Nasdaq Global Select Market under symbol STTK.